However, the NPPA can only fix the price of a drug or device once DoP issues a notification. Ltd and Boston Scientific Corp. Stent manufacturers selling their wares with exorbitant mark-ups of between 100%-300% is the norm, according to industry experts. The foreign stent device manufacturers have inundated the Prime Minister’s Office, NITI Aayog and the respective ministries with their representations. Mails sent to the DoP secretary Jai Priye Prakash about the reasons behind the delay in issuing the notification went unanswered. The medical devices industry has been fighting the impending price cap on stents as it would imply reduced margins, and has pushed for differential pricing of price stents.

Source: Mint November 24, 2016 19:20 UTC